Efficacy and Safety Evaluation of Pazopanib in Maintenance Therapy after Plat-inum-resistant Recurrence of Ovarian Cancer
- VernacularTitle:帕唑帕尼在卵巢癌铂耐药复发后维持治疗中的疗效和安全性评价
- Author:
Yumei LIU
1
;
Ruiqi DUAN
Author Information
1. 四川友谊医院妇科,四川 成都 610066
- Publication Type:Journal Article
- Keywords:
Pazopanib;
Ovarian cancer;
Platinum resistance;
Recurrence;
Progression-free survival
- From:
Journal of Practical Obstetrics and Gynecology
2025;41(3):259-262
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of Pazopanib in maintenance therapy after platinum-resistant recurrence of ovarian cancer.Methods:A total of 80 patients with platinum-resistant recurrence of ovarian cancer treated in Sichuan Friendship Hospital from January 2018 to January 2024 were selected as the study objects.All patients were given paclitaxel or gemcitabine monotherapy for 6-8 cycles and entered mainte-nance therapy after the patients achieved complete response(CR)or partial response(PR).They were divided into a study group(38 cases)and a control group(42 cases)using a simple randomization method.The study group was given pazopanib maintenance treatment,and the control group was given compound cantharides cap-sule maintenance treatment.The treatment time lasted until the disease progressed.Progression-free survival(PFS),serum CA125 level,1-year survival rate,and adverse drug reactions were compared between the two groups.Results:Compared with the control group,PFS(12.84±6.23 months vs.6.12±4.82 months)and 1-year survival rate(73.68%vs.45.24%)in the study group were higher than those in the control group,the difference was statistically significant(P<0.05).The serum CA125 level of the study group was lower than that of the control group after 3 months of maintenance treatment and when the tumor recurred again,and the difference was statis-tically significant(P<0.05).The overall incidence of adverse drug reactions in the study group was higher than that in the control group(52.63%vs.21.42%,P<0.05),but mainly chronic diarrhea,hair loss and hypopigmenta-tion.Conclusions:In the maintenance treatment after recurrence of platinum-resistant patients with ovarian canc-er,oral pazopanib can effectively prolong the disease progression-free period of patients with few side effects,high safety,and strong patient compliance.
